LA in Special Groups - The Ground Rules
- Altered pharmacokinetics: Expect changes in absorption, distribution (e.g., altered Vd), metabolism (↓ hepatic/renal clearance), and excretion.
- Altered pharmacodynamics: Nerve sensitivity is often ↑ (e.g., elderly, pregnancy), affecting LA potency/duration.
- Guiding principles:
- Adopt "start low, go slow" dosing.
- Crucial: meticulous monitoring for early CNS/CVS toxicity signs.
- Proactive dose reduction is key.
⭐ Special populations often have a narrower therapeutic window for LAs, demanding careful titration and heightened vigilance.
Pediatric Patients - Tiny Patients, Big Care
- Pharmacokinetic Differences:
- ↑ Volume of distribution (Vd) (larger Extracellular Fluid).
- ↓ Protein binding (esp. neonates due to ↓ alpha-1-acid glycoprotein) → ↑ free drug fraction.
- ↓ Hepatic metabolism (immature P450 enzymes).
- ↓ Renal excretion (immature Glomerular Filtration Rate).
- Increased Toxicity Risk:
- Higher susceptibility to systemic toxicity.
- ⚠️ Prilocaine/Benzocaine: Risk of methemoglobinemia (avoid in infants <6 months).
- Maximum Recommended Doses (mg/kg):
Anesthetic Plain With Epinephrine Lidocaine 3-5 5-7 Bupivacaine 1.5-2 2-2.5 Ropivacaine 2-3 2-3
⭐ Neonates exhibit decreased levels of alpha-1-acid glycoprotein, leading to a higher free fraction of local anesthetics and an increased risk of toxicity.
Geriatric Patients - Golden Years, Gentle Doses
- Physiological Considerations:
- Reduced organ function (hepatic, renal) → ↓ LA clearance, ↑ half-life.
- Decreased lean body mass, increased body fat → ↑ volume of distribution for lipid-soluble LAs.
- Altered protein binding (↓ albumin) → ↑ unbound, active LA.
- Increased sensitivity of nervous tissue.
- Polypharmacy → potential drug interactions.
- Pharmacokinetic Changes:
- Slower onset of action.
- Longer duration of effect.
- Dosing Strategy: Reduce dose by 20-50%. Titrate slowly.
⭐ Geriatric patients show increased susceptibility to CNS toxicity (e.g., confusion, agitation) and cardiotoxicity from LAs.
Pregnancy & Lactation - Two Lives, One Plan
Physiological changes: ↑ CO, ↑ GFR, ↑ Vd; ↓ protein binding (↑ free drug).
- ⚠️ Increased sensitivity to LA neurotoxicity & cardiotoxicity (e.g., Bupivacaine).
Placental Transfer:
- Factors: ↑ lipid solubility, ↓ ionization, ↓ protein binding, ↓ molecular weight (📌 LIMP).
- Ion trapping: Fetal acidosis traps LAs (weak bases) in ionized form. $pH - pKa = log([A^-]/[HA])$.
⭐ Progesterone increases neuronal sensitivity to local anesthetics during pregnancy.
LA Safety Profile:
| Setting | Preferred LAs | Notes |
|---|---|---|
| Labor Analgesia | Bupivacaine, Ropivacaine | Epidural/spinal; monitor for toxicity |
| Lidocaine | Perineal infiltration | |
| Lactation | Lidocaine, Bupivacaine, Ropivacaine | Generally safe; low milk excretion |
Co-morbid Conditions - Tricky Terrains
| Co-morbidity | LA Choice & Dose Adjustment | Key Precautions & Monitoring |
|---|---|---|
| Hepatic Disease | Amides (e.g., lidocaine): ↓ dose due to impaired metabolism. | Monitor for CNS/cardiac toxicity. Esters preferred in severe disease. |
| Renal Disease | Repeated doses: caution. Risk of active metabolite accumulation. | Monitor for systemic toxicity, esp. with mepivacaine, prilocaine. |
| Cardiac Disease | ↓ LA dose. Limit/avoid epinephrine with arrhythmias/ischemia. | Arrhythmogenic potential. Continuous ECG. Careful vasoconstrictor use. |
| Respiratory Disease | High neuraxial/interscalene blocks: use cautiously. | Risk of phrenic nerve palsy, respiratory depression. Monitor ventilation. |
| Pseudocholinesterase Def. | Esters (procaine, tetracaine): avoid or drastically ↓ dose. | Prolonged LA effect/paralysis. Prefer amides. Monitor neuromuscular function. |
High‑Yield Points - ⚡ Biggest Takeaways
- Pregnancy: Bupivacaine has ↑ cardiotoxicity; Lidocaine (Cat B) safer. Avoid high-dose Prilocaine (methemoglobinemia).
- Pediatrics: Neonates: ↓ AAG, immature liver. Use precise weight-based dosing. Max lidocaine 4.5 mg/kg.
- Geriatrics: ↓ clearance necessitates LA dose reduction (e.g., 20-50%).
- Severe Liver Disease: Reduce amide LA dose significantly; ester LAs are safer.
- Renal Failure: Amide LA dose often unchanged; active metabolites may accumulate.
- Pseudocholinesterase Deficiency: Avoid ester LAs (prolonged action); prefer amides.
- Obesity: Dose LAs based on Ideal Body Weight (IBW) to prevent toxicity.
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more
